Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
OBJECTIVE
The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in several malignances. Both docetaxel and cisplatin are active in gastric cancer. A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ).


METHODS
Forty-four chemotherapy-naïve patients with Eastern Cooperative Oncology Group performance status 0 or 1, of whom 80% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, were enrolled. The treatment regimen was sorafenib 400 mg orally twice a day for 21 days, docetaxel 75 mg/m(2) intravenously on day 1, and cisplatin 75 mg/m(2) intravenously on day 1, repeated every 21 days. The primary end point was response rate to the combination. Toxicity, overall survival, and progression-free survival were assessed as secondary end points.


RESULTS
Eighteen of the 44 eligible and treated patients showed partial responses (41%; 90% CI, 28% to 54%). The median progression-free survival was 5.8 months (90% CI, 5.4 to 7.4 months). The median overall survival was 13.6 months (90% CI, 8.6 to 16.1 month). The major toxicity of this regimen was neutropenia, which reached grade 3 to 4 in 64% of patients. One patient experienced hemorrhage at the tumor site.


CONCLUSIONS
The combination of sorafenib, docetaxel, and cisplatin has an encouraging efficacy profile with tolerable toxicity. Additional studies of sorafenib with chemotherapy are warranted in gastric cancer.
Sun
Weijing
W
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104-4283, USA. weijing.sun@uphs.upenn.edu
Powell
Mark
M
O'Dwyer
Peter J
PJ
Catalano
Paul
P
Ansari
Rafat H
RH
Benson
Al B
AB
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004943:Esophagogastric Junction / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D000077157:Sorafenib; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D043823:Taxoids; D000077143:Docetaxel; D009536:Niacinamide; D000077157:Sorafenib; D002945:Cisplatin
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
J Clin Oncol. 2007 Aug 1;25(22):3217-23
17664469
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Clin Lung Cancer. 2007 May;8(6):396-8
17562243
N Engl J Med. 2002 Aug 15;347(7):481-7
12181402
Nature. 2002 Jun 27;417(6892):949-54
12068308
N Engl J Med. 2008 Jan 3;358(1):36-46
18172173
J Clin Invest. 2003 May;111(9):1287-95
12727920
Mol Cancer Ther. 2008 Oct;7(10):3129-40
18852116
J Clin Oncol. 2009 Mar 10;27(8):1280-9
19171708
Nat Rev Cancer. 2002 Oct;2(10):795-803
12360282
J Clin Oncol. 2009 Sep 10;27(26):4274-80
19652055
Clin Cancer Res. 2008 Aug 1;14(15):4836-42
18676756
Ann Oncol. 2009 Apr;20(4):666-73
19153121
Br J Cancer. 1999 Apr;80(1-2):269-72
10390007
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Br J Surg. 1998 Nov;85(11):1457-9
9823902
Eur J Cancer. 2007 Jan;43(1):55-63
17095207
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530
J Clin Oncol. 2006 Nov 1;24(31):4991-7
17075117
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206